These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 10352118

  • 1. Vitamin D and prostate cancer.
    Blutt SE, Weigel NL.
    Proc Soc Exp Biol Med; 1999 Jun; 221(2):89-98. PubMed ID: 10352118
    [Abstract] [Full Text] [Related]

  • 2. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
    Skowronski RJ, Peehl DM, Feldman D.
    Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
    [Abstract] [Full Text] [Related]

  • 3. Human prostate cancer cells: inhibition of proliferation by vitamin D analogs.
    Schwartz GG, Oeler TA, Uskoković MR, Bahnson RR.
    Anticancer Res; 1994 Jan; 14(3A):1077-81. PubMed ID: 8074453
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of vitamin D analogs as therapeutic agents for prostate cancer.
    Chen TC, Holick MF, Lokeshwar BL, Burnstein KL, Schwartz GG.
    Recent Results Cancer Res; 2003 Jan; 164():273-88. PubMed ID: 12899529
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089.
    Lokeshwar BL, Schwartz GG, Selzer MG, Burnstein KL, Zhuang SH, Block NL, Binderup L.
    Cancer Epidemiol Biomarkers Prev; 1999 Mar; 8(3):241-8. PubMed ID: 10090302
    [Abstract] [Full Text] [Related]

  • 8. Vitamin D receptor-dependent antitumour effects of 1,25-dihydroxyvitamin D3 and two synthetic analogues in three in vivo models of prostate cancer.
    Oades GM, Dredge K, Kirby RS, Colston KW.
    BJU Int; 2002 Oct; 90(6):607-16. PubMed ID: 12230626
    [Abstract] [Full Text] [Related]

  • 9. Vitamin D compounds: clinical development as cancer therapy and prevention agents.
    Trump DL, Muindi J, Fakih M, Yu WD, Johnson CS.
    Anticancer Res; 2006 Oct; 26(4A):2551-6. PubMed ID: 16886663
    [Abstract] [Full Text] [Related]

  • 10. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer.
    Li H, Stampfer MJ, Hollis JB, Mucci LA, Gaziano JM, Hunter D, Giovannucci EL, Ma J.
    PLoS Med; 2007 Mar; 4(3):e103. PubMed ID: 17388667
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Antitumor effects of two less-calcemic vitamin D analogs (Paricalcitol and QW-1624F2-2) in squamous cell carcinoma cells.
    Alagbala AA, Johnson CS, Trump DL, Posner GH, Foster BA.
    Oncology; 2006 Mar; 70(6):483-92. PubMed ID: 17237623
    [Abstract] [Full Text] [Related]

  • 15. Vitamin D in Prostate Cancer.
    Ahn J, Park S, Zuniga B, Bera A, Song CS, Chatterjee B.
    Vitam Horm; 2016 Mar; 100():321-55. PubMed ID: 26827958
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Antiproliferative role of vitamin D and its analogs--a brief overview.
    Banerjee P, Chatterjee M.
    Mol Cell Biochem; 2003 Nov; 253(1-2):247-54. PubMed ID: 14619976
    [Abstract] [Full Text] [Related]

  • 18. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
    Chen TC, Schwartz GG, Burnstein KL, Lokeshwar BL, Holick MF.
    Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.